Badlaeva Alina, Tregubova Anna, Palicelli Andrea, Asaturova Aleksandra
National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of the Ministry of Health of Russia, Bldg. 4, Oparina Street, 117513 Moscow, Russia.
Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Cancers (Basel). 2024 Jun 25;16(13):2322. doi: 10.3390/cancers16132322.
According to recent reports, ovarian serous borderline tumor (SBT) harboring the V600E mutation is associated with a lower risk of progression to low-grade serous carcinoma. Preliminary observations suggest that there may be an association between eosinophilic cells (ECs) and the above-mentioned mutation, so this study aimed to evaluate interobserver reproducibility for assessing ECs. Forty-two samples of SBTs were analyzed for ECs with abundant eosinophilic cytoplasm. Immunohistochemical staining and genetic pro-filing were performed in all cases to verify the V600E mutation. A V600E mutation was found in 19 of 42 (45%) cases. Inter-observer reproducibility in the assessment of ECs was substantial (κ = 0.7). The sensitivity and specificity for predicting the mutation were 79% and 91%, respectively. Patients with -mutated SBTs were significantly younger than those without mutation ( = 0.005). SBTs with mutation were less likely to be accompanied by non-invasive implants than wild-type SBT: 12% (2/17) versus 33% (6/18). Seven cases were excluded due to incomplete cytoreductive surgery. Nevertheless, Fisher's exact test showed no significant differences between the two groups ( = 0.228). Overall, this study strengthens the idea that ECs in ovarian SBTs may represent a mutation with prognostic significance, which can serve as a primary screening test for V600E mutation in this pathologic entity.
根据最近的报告，携带V600E突变的卵巢浆液性交界性肿瘤（SBT）进展为低级别浆液性癌的风险较低。初步观察表明，嗜酸性细胞（ECs）与上述突变之间可能存在关联，因此本研究旨在评估观察者间评估ECs的可重复性。对42例具有丰富嗜酸性细胞质的SBT样本进行ECs分析。所有病例均进行免疫组织化学染色和基因分析以验证V600E突变。42例病例中有19例（45%）发现V600E突变。观察者间评估ECs的可重复性较高（κ=0.7）。预测该突变的敏感性和特异性分别为79%和91%。携带突变的SBT患者明显比未突变患者年轻（P=0.005）。与野生型SBT相比，携带突变的SBT伴随非侵袭性种植的可能性较小：12%（2/17）对33%（6/18）。7例因细胞减灭术不完全而被排除。尽管如此，Fisher精确检验显示两组之间无显著差异（P=0.228）。总体而言，本研究强化了这样一种观点，即卵巢SBT中的ECs可能代表一种具有预后意义的突变，可作为该病理实体中V600E突变的初步筛查检测。
